Caleb Davis, DPM
Foot & Ankle Surgery · Portsmouth, OHNPI 1528416427
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Vilex LLC at 36.0% of the total. Reporting peaked in 2024 at $4,258 and has fallen 96.0% since, to $172 in 2025.
Across 79 payments — averaging $146.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vilex LLC$4K
- Arthrex$3K
- Paragon 28, Inc.$1K
- CDC Medical LLC$1K
- Treace Medical Concepts, Inc.$1K
- Stryker$779
- plus $264 from 5 others
What the payments were for
- Consulting fees$2,25019%
- Travel & lodging$5,93051%
- Food & beverage$2,21619%
- Education$1,20010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vilex LLC | 12 | $4,177 |
| Arthrex | 23 | $2,644 |
| Paragon 28, Inc. | 4 | $1,329 |
| CDC Medical LLC | 13 | $1,254 |
| Treace Medical Concepts, Inc. | 12 | $1,150 |
| Stryker | 7 | $779 |
| Zimmer Biomet | 2 | $81 |
| Heron Therapeutics, Inc. | 1 | $72 |
| Biocomposites Inc | 1 | $48 |
| Organogenesis Inc. | 2 | $33 |
| Smith+Nephew | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIS Distal Bunion - R&D$2,700
- Portfolio$1,262
- HINTERMANN$1,207
- Lapiplasty System$824
- HOFFMANN$557
- ALLOWRAP$130
How this compares
$11,596 in reported general payments places this provider in the 80th percentile of 429 foot & ankle surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 33 | $408 |
| Cefdinir | 32 | $328 |
| Ondansetron OdtOndansetron | 37 | $303 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $220 |
| Doxycycline Hyclate | 30 | $181 |
| Gabapentin | 27 | $160 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $150 |
| Methylprednisolone | 21 | $90 |
| Triamcinolone Acetonide | 11 | $62 |
| Cyclobenzaprine Hcl | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Portsmouth
- Christopher HyerWorthington$4.7M
- Thomas LeePickerington$4M
- Jordan GrossmanAkron$2.5M
- Robert GorslineHilliard$1.4M
- Jonathan FeibelGahanna$1.4M
- Mark PrisselWorthington$1.2M
- Lee HladGahanna$440K
- Windy ColeKent$431K
- Elizabeth HewittGrove City$414K
- Dominic RizzoBlue Ash$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.